Biological actions of pentraxins (Q38472979)

3 September 2017

1 reference

title

Biological actions of pentraxins (English)

1 reference

3 September 2017

Gemma Vilahur

1

1 reference

3 September 2017

Lina Badimon

series ordinal

2

1 reference

3 September 2017

publication date

8 May 2015

1 reference

3 September 2017

published in

Vascular Pharmacology

1 reference

3 September 2017

volume

73

1 reference

3 September 2017

page(s)

38-44

1 reference

Ischemia/reperfusion activates myocardial innate immune response: the key role of the toll-like receptor

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Pentraxin 3(PTX 3): an endogenous modulator of the inflammatory response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

SEROLOGICAL REACTIONS IN PNEUMONIA WITH A NON-PROTEIN SOMATIC FRACTION OF PNEUMOCOCCUS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

IMMUNOLOGIC STUDIES ON A PROTEIN EXTRACTED FROM HUMAN SECONDARY AMYLOID

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Evolution of the pentraxin family: the new entry PTX4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Dissociation of Pentameric to Monomeric C-Reactive Protein on Activated Platelets Localizes Inflammation to Atherosclerotic Plaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Endogenous Expression of C-Reactive Protein Is Increased in Active (Ulcerated Noncomplicated) Human Carotid Artery Plaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

C-reactive protein: a critical update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Protective Role of Interleukin-10 in Atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaos

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Regulation of PTX3, a key component of humoral innate immunity in human dendritic cells: stimulation by IL-10 and inhibition by IFN-

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Pattern recognition by pentraxins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Structure and function of the long pentraxin PTX3 glycosidic moiety: fine-tuning of the interaction with C1q and complement activation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Biochemical and functional characterization of the interaction between pentraxin 3 and C1q.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Synergy between ficolin-2 and pentraxin 3 boosts innate immune recognition and complement deposition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Production of the long pentraxin PTX3 in advanced atherosclerotic plaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Relation of C-reactive protein to coronary plaque characteristics on grayscale, radiofrequency intravascular ultrasound, and cardiovascular outcome in patients with acute coronary syndrome or stable angina pectoris (from the ATHEROREMO-IVUS study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Different distribution of pentraxin 3 and C-reactive protein in coronary atherosclerotic plaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Modified C-reactive protein is expressed by stroke neovessels and is a potent activator of angiogenesis in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

C-reactive protein exerts angiogenic effects on vascular endothelial cells and modulates associated signalling pathways and gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Direct proinflammatory effect of C-reactive protein on human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Lipopolysaccharide (LPS) contamination plays the real role in C-reactive protein-induced IL-6 secretion from human endothelial cells in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Relation between the plasma levels of LDL-cholesterol and the expression of the early marker of inflammation long pentraxin PTX3 and the stress response gene p66ShcA in pacemaker-implanted patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Plasma pentraxin 3 is a more potent predictor of endothelial dysfunction than high-sensitive C-reactive protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Pentraxin 3 Induces Vascular Endothelial Dysfunction Through a P-selectin/Matrix Metalloproteinase-1 Pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Short-term myocardial ischemia induces cardiac modified C-reactive protein expression and proinflammatory gene (cyclo-oxygenase-2, monocyte chemoattractant protein-1, and tissue factor) upregulation in peripheral blood mononuclear cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Molecular and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

PTX3 expression in the heart tissues of patients with myocardial infarction and infectious myocarditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Cardioprotective Function of the Long Pentraxin PTX3 in Acute Myocardial Infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Regulation of leukocyte recruitment by the long pentraxin PTX3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

HMG-CoA reductase inhibition prior reperfusion improves reparative fibrosis post-myocardial infarction in a preclinical experimental model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Proliferation of neointimal smooth muscle cells after arterial injury. Dependence on interactions between fibroblast growth factor receptor-2 and fibroblast growth factor-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Monomeric C-reactive protein and Notch-3 co-operatively increase angiogenesis through PI3K signalling pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

C-reactive protein isoforms differ in their effects on thrombus growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Opposing effects of C-reactive protein isoforms on shear-induced neutrophil-platelet adhesion and neutrophil aggregation in whole blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Monomeric C-reactive protein is prothrombotic and dissociates from circulating pentameric C-reactive protein on adhered activated platelets under flow.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Monomerization of C-reactive protein requires glycoprotein IIb-IIIa activation: pentraxins and platelet deposition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Conversion of native oligomeric to a modified monomeric form of human C-reactive protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Circulating microparticles generate and transport monomeric C-reactive protein in patients with myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Binding of carboxypeptidase N to fibrinogen and fibrin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

Atorvastatin reduces long pentraxin 3 expression in vascular cells by inhibiting protein geranylgeranylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.001

10.1016/J.VPH.2015.05.001

7 January 2021

Identifiers

DOI

1 reference

3 September 2017

1 reference